Innovation Tracking Factbook 2017 - An Assessment of the Pharmaceutical Pipeline
Albany, New York, Feb 28, 2017
"Innovation
Tracking Factbook 2017 - An Assessment of the Pharmaceutical
Pipeline"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
GBI
Research’s latest report: “Innovation Tracking Factbook 2017: An
Assessment of the Pharmaceutical Pipeline” is a comprehensive,
granular analysis of the 20,756 products currently in the
pharmaceutical industry pipeline, from the Discovery stage through to
Pre-registration and split into therapy areas and key indications.
This pipeline is also benchmarked against its size across each
segment in 2015, and an assessment of the level of first-in-class
innovation is provided. In addition, a detailed contextual analysis
of the key drivers of this pipeline is provided, in addition to an
assessment of companies present in the pipeline and historical deal
value and volume.
Innovation,
particularly the development of new products, is a crucial element of
the pharmaceutical industry. The market is highly research-intensive,
being deeply reliant on a high level of R&D investment and a
strong product pipeline to maintain growth and ensure long-term
revenue generation. Without successful innovation, which can be
broadly defined as the market launch of novel therapeutic molecules
that cost-effectively treat or cure diseases, the industry would face
a substantial long-term decline in revenue.
A particular focus of this report is placed on
analysis of the development of innovative drugs, specifically
first-in-class innovation. Over recent decades, in addition to an
increase in the yearly number of new chemical entity approvals by the
FDA, the number and proportion of these approvals that were
first-in-class at the time of approval have also increased. The
proportion of first-in-class approvals has increased steadily each
year since 1994, with the exception of the years 2005–2008, when
the proportion was relatively high.
– Scope
- What is the current size and composition of the pharmaceutical industry pipeline and how has it changed since Q1 2015? What can we learn from this?
- The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
- What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
- What factors have been driving the increasing number of first-in-class product approvals over recent decades?
- What strategies have companies typically been pursuing with their pipeline portfolio, in terms of how diverse, specialized or innovative they have been? Specifically, what strategies have the top 25 pharmaceutical companies been following?
- What key discernible trends have appeared in the strategic consolidations landscape in the past decade and which disease areas have been most active?
** Reasons To Buy
– This report will allow you to:
- Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
- Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one’s own strategic positioning against this backdrop
- Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
- Make key decisions about the role of innovation within one’s own pipeline portfolio
–
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 5
2.1 Increasing Cost of Drug Development 7
2.2 Most Drugs Fail to Recuperate R&D Costs 8
2.3 Contracting Life Cycles for Approved Products 9
2.4 The Case for First-in-Class Pharmaceutical Innovation 10
2.5 Conclusion 13
2.1 Increasing Cost of Drug Development 7
2.2 Most Drugs Fail to Recuperate R&D Costs 8
2.3 Contracting Life Cycles for Approved Products 9
2.4 The Case for First-in-Class Pharmaceutical Innovation 10
2.5 Conclusion 13
3 Assessment of the Pharmaceutical
Industry Pipeline 14
3.1 Pipeline and Clinical Trials Landscape by Therapy Area 14
3.2 Pipeline by Stage of Development 19
3.3 Pipeline by Molecule Type 22
3.4 Key Therapy Areas by Indication 26
3.4.1 Oncology 26
3.4.2 Infectious Diseases 28
3.4.3 Central Nervous System 29
3.4.4 Immunology 32
3.5 Conclusion 33
3.1 Pipeline and Clinical Trials Landscape by Therapy Area 14
3.2 Pipeline by Stage of Development 19
3.3 Pipeline by Molecule Type 22
3.4 Key Therapy Areas by Indication 26
3.4.1 Oncology 26
3.4.2 Infectious Diseases 28
3.4.3 Central Nervous System 29
3.4.4 Immunology 32
3.5 Conclusion 33
4 Assessment of Innovation in the
Pharmaceutical Industry Pipeline 34
4.1 First-in-Class Innovation by Stage of Development 36
4.2 Key Therapy Areas by Indication 38
4.2.1 Oncology 38
4.2.2 Infectious Diseases 41
4.2.3 Central Nervous System 43
4.2.4 Immunology 47
4.3 Conclusion 49
4.1 First-in-Class Innovation by Stage of Development 36
4.2 Key Therapy Areas by Indication 38
4.2.1 Oncology 38
4.2.2 Infectious Diseases 41
4.2.3 Central Nervous System 43
4.2.4 Immunology 47
4.3 Conclusion 49
5 Company Analysis 50
5.1 Conclusion 54
5.1 Conclusion 54
Comments
Post a Comment